Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06228391 · ClinicalTrials.gov registry record · Phase 2
Ketamine Treatment for PTSD and MDD in TBI
A Phase 2 study, sponsored by Minneapolis Veterans Affairs Medical Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT06228391 is a Phase 2 study that has not yet begun recruiting, run by Minneapolis Veterans Affairs Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT06228391, a Phase 2 study, has not yet begun recruiting, sponsored by Minneapolis Veterans Affairs Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to examine the use of sedative ketamine to treat depression and post-traumatic stress disorder (PTSD) in Veterans with mild to moderate traumatic brain injury (TBI). The main questions it aims to answer are: * Efficacy of ketamine to reduce symptoms of depression and/or PTSD * Safety of ketamine to treat depression and/or PTSD in TBI Participants will be randomly assigned to receive either ketamine or midazolam (active placebo) twice a week for 3 weeks. During participation, subjects will be interviewed, have lab tests, and complete rating scales, and questionnaires.
Interventions
- DRUG Midazolam
- DRUG IV ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-03 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06228391
The ClinicalTrials.gov registry entry for NCT06228391 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Minneapolis Veterans Affairs Medical Center, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT06228391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06228391 about?
NCT06228391 is a clinical study titled "Ketamine Treatment for PTSD and MDD in TBI". The goal of this clinical trial is to examine the use of sedative ketamine to treat depression and post-traumatic stress disorder (PTSD) in Veterans with mild to moderate traumatic brain injury (TBI). The main questions it aims to answer are: * Efficacy of ketamine to reduce symptoms of depression ...
What is the current status of trial NCT06228391?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-03. Estimated completion is 2027-03.
What interventions are being tested in trial NCT06228391?
The interventions under investigation include: Midazolam (DRUG), IV ketamine (DRUG).
Who is sponsoring clinical trial NCT06228391?
This trial is sponsored by Minneapolis Veterans Affairs Medical Center, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.